Materiały źródłowe

• #1 Cardiomyopathy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/cardiomyopathy/diagnosis-treatment/drc-20370714

  The goals of cardiomyopathy treatment are to: […] The type of treatment depends on the type of cardiomyopathy and how serious it is. […] Many types of medicines are used to treat cardiomyopathy. Medicines for cardiomyopathy can help: […] Ways to treat cardiomyopathy or an irregular heartbeat without surgery include: […] Somes types of devices can be placed in the heart with surgery. They can help the heart work better and relieve symptoms. Some help prevent complications. Types of cardiac devices include: […] Types of surgery used to treat cardiomyopathy include:

• #2 Cardiomyopathy: Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/16841-cardiomyopathy

  Cardiomyopathy treatment can slow the progression and improve your quality of life. […] Treatment can help. Some people with cardiomyopathy eventually need a heart transplant. […] Cardiomyopathy treatments dont cure the condition. However, they can help you manage your symptoms and slow down the diseases progression. Your healthcare provider may recommend lifestyle changes, medications, devices or procedures. […] Depending on the cause, specific case, your cardiomyopathy and any other underlying medical conditions, certain medications can improve your blood flow and manage your symptoms. […] If you have severe symptoms or underlying heart conditions, your provider may recommend a procedure. Some of these involve surgery. Providers usually only recommend open-heart surgery or a heart transplant when all other treatments have failed to bring relief.

• #3 Cardiomyopathy – Treatment | NHLBI, NIH

  https://www.nhlbi.nih.gov/health/cardiomyopathy/treatment

  If your healthcare provider recommends treatment, your treatment plan will depend on the type of cardiomyopathy you have, how serious it is, and whether you have any complications. Talk with your provider about your needs and goals so the treatment plan will work for you. […] Treatment for cardiomyopathy might not cure the problem with your heart. The main goals of treatment are to: […] Your treatment may include medicines, procedures, and devices. Patients with cardiomyopathy or heart failure should see a cardiologist consultation to help manage their disease. […] The following medicines can help treat symptoms of different types of cardiomyopathies. […] Talk with your provider about a procedure or device if medicines don’t help improve your symptoms. […] Cardiomyopathy increases the risk of life-threatening events such as cardiac arrest or cardiogenic shock. If you have complications, such as an arrhythmia or heart failure, you may need a surgically implanted device, such as a left ventricular assist device, an implanted cardioverter defibrillator (ICD), or a pacemaker to help keep you safe. […] You may need a heart transplant if you have life-threatening symptoms or complications of cardiomyopathy, and no other treatments have worked for you.

• #4 Prevention and Treatment of Cardiomyopathy | American Heart Association

  https://www.heart.org/en/health-topics/cardiomyopathy/prevention-and-treatment-of-cardiomyopathy

  People who have cardiomyopathy, but no signs or symptoms, may not need treatment. Sometimes, dilated cardiomyopathy that comes on suddenly may go away on its own. […] In other instances, treatment is needed. Treatment hinges on a few factors: […] When treating cardiomyopathy, objectives include: […] Treatment for cardiomyopathy may include one or more of the following: […] Lifestyle changes may help manage a condition that’s causing your cardiomyopathy. […] Many medications are used to treat cardiomyopathy. Depending on the type of cardiomyopathy, your health care professional may prescribe medicines to: […] A range of surgical and nonsurgical procedures can be used to treat cardiomyopathy: […] Cardiomyopathy can be caused by an underlying disease or condition. Treating that initial problem early may help prevent the complications presented by cardiomyopathy.

• #5 Medication for Cardiomyopathy & Heart Failure | NYU Langone Health

  https://nyulangone.org/conditions/cardiomyopathy-heart-failure/treatments/medication-for-cardiomyopathy-heart-failure

  Cardiomyopathy and heart failure affect the hearts ability to pump blood and oxygen throughout the body. Your NYU Langone specialist may prescribe medication to improve heart function and manage the symptoms of these conditions. […] Angiotensin-converting enzyme inhibitors also called ACE inhibitors may be prescribed for people who have heart failure with reduced ejection fraction, which is also called dilated cardiomyopathy. These medications widen, or dilate, blood vessels to improve blood flow. They can help prevent further weakening of the heart by blocking angiotensin, a hormone that can damage the heart. […] Angiotensin II receptor blockers help relax and widen blood vessels and reduce salt and water retention. Our doctors may recommend these medications to people with heart failure with reduced ejection fraction who can’t tolerate ACE inhibitors.

• #6 Current Management and Treatment – Dilated Cardiomyopathy – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK553842/

  DCM is a common cause of HF and treatment reflects the management of chronic HF. DCM patients, indeed, can be divided into two different classes on the base of the presence of clinical symptoms: Asymptomatic left ventricular systolic dysfunction: in patients with depressed LV systolic function in the absence of symptoms, onset of HF should be delayed or prevented primarily by controlling hypertension and, when the LVEF is 40%, by initiating angiotensin-converting enzyme inhibitor (ACEi) therapy prior to beta-blocker therapy, since the evidences supporting ACEi therapy are stronger. Symptomatic HF with reduced ejection fraction: patients of this category should all be treated. The goals of therapy are to reduce mortality and morbidity; improve symptoms, quality of life, and functional status and decrease hospitalization rate.

• #6 Current Management and Treatment – Dilated Cardiomyopathy – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK553842/

  The prevalence of heart failure (HF) is escalating rapidly, consuming significant healthcare resources, inflicts significant morbidity and mortality, and greatly impacts quality of life. Dilated cardiomyopathy (DCM) is a frequent cause of HF and is characterized by a progressive course. Nowadays pharmacological and non-pharmacological therapies have dramatically changed DCMs natural history. […] Patients with a clinical diagnosis of HF and LV dysfunction should receive recommended therapies: beta-blockers (BB), ACE inhibitors (ACEi) or angiotensin receptor blockers (ARB), aldosterone antagonists, and more recently angiotensin receptor-neprilysin inhibitor (ARNI) and ivabradine are established therapies for chronic HF. In case of persistent systolic dysfunction and/or severe intraventricular conduction delay, an ICD and/or CRT are indicated. Finally, heart transplantation and mechanical circulatory support (MCS) are options that can be used in critically ill HF who cant be stabilized by medical therapy alone.

• #7 Medication for Cardiomyopathy & Heart Failure | NYU Langone Health

  https://nyulangone.org/conditions/cardiomyopathy-heart-failure/treatments/medication-for-cardiomyopathy-heart-failure

  Often prescribed in conjunction with ACE inhibitors for heart failure with reduced ejection fraction, beta blockers lessen the hearts workload by preventing the hormone adrenaline from increasing the heart rate in response to stress also known as the fight or flight reaction. These medications can help protect the heart from further damage over time. […] Diuretics may be prescribed for people with any type of heart failure. These medications eliminate excess fluid from the body by encouraging the production of urine. This helps reduce swelling and shortness of breath, which occurs when blood backs up into the lungs. […] Your doctor may also prescribe mineralocorticoid receptor antagonists, which can help regulate fluid retention while ensuring that potassium levels don’t drop too low. These medications also protect the heart from further damage over time.

• #8 Dilated Cardiomyopathy (DCM) Treatment & Management: Approach Considerations, Blood Pressure Control, Angiotensin-Converting Enzyme Inhibitors

  https://emedicine.medscape.com/article/152696-treatment

  Treatment of DCM is essentially the same as treatment of chronic HF and pulmonary edema; however, obtaining a thorough history from patients with DCM helps determine the etiology. […] Mainstays of medical therapy are preload reduction, afterload reduction, diuresis, and airway support. […] Appropriate control of blood pressure is essential to effective therapy for persons with HF. […] Use of angiotensin-converting enzyme (ACE) inhibitors has been the criterion standard in the treatment of left ventricular dysfunction. […] ACE inhibitors have been shown to decrease mortality in both symptomatic and asymptomatic patients with left ventricular dysfunction and to reduce readmissions caused by HF. […] Data have demonstrated that angiotensin II receptor blockers (ARBs) are as effective as angiotensin-converting enzyme (ACE) inhibitors in the treatment of HF.

• #8 Dilated Cardiomyopathy (DCM) Treatment & Management: Approach Considerations, Blood Pressure Control, Angiotensin-Converting Enzyme Inhibitors

  https://emedicine.medscape.com/article/152696-treatment

  An integral part of managing patients with cardiomyopathy is identifying and managing their risk factors and comorbid conditions. […] Treatment of dilated cardiomyopathy (DCM) is essentially the same as treatment of chronic HF, a complex clinical syndrome for which many treatment modalities have emerged. […] Drug classes used to manage cardiomyopathies include, but are not limited to, the following: Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs), Beta-blockers, Aldosterone antagonists, Cardiac glycosides, Diuretics, Nitrates, Vasodilators, Sacubitril/valsartan (ARNI), Ivabradine, Antiarrhythmics, Human B-type natriuretic peptide, Inotropic agents, Anticoagulants (may be used in selected patients). […] Various surgical options are available for patients with disease refractory to medical therapy. These include the following: Left ventricular assist devices, Cardiac resynchronization therapy (biventricular pacing), Automatic implantable cardioverter-defibrillators, Ventricular restoration surgery, Heart transplantation.

• #9 Treatment of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to Know

  https://www.acc.org/Latest-in-Cardiology/Articles/2020/02/19/18/19/Treatment-of-Hypertrophic-Cardiomyopathy

  Treatment of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to Know […] Hypertrophic cardiomyopathy (HCM) is an inherited disease of the cardiac sarcomere that results in left ventricular hypertrophy, hyperdynamic function, microvascular dysfunction, impaired relaxation, and myocardial fibrosis. Clinical hallmarks include left ventricular outflow tract obstruction (LVOTO), arrhythmias, and heart failure. To date, no disease-modifying therapies have been identified, although clinical trials of novel therapeutics are in progress. This analysis focuses on HCM management strategies fundamental to the care of patients with HCM: LVOTO, sudden cardiac death (SCD), atrial fibrillation, exercise restriction, and heart failure. […] A significant proportion of HCM patients suffer from LVOTO; therefore, investigating obstruction with both resting echo (with Valsalva) and stress echo if the gradient is below 50mmHg on rest interrogation should be performed. Treatment of obstruction is indicated for symptomatic patients (NYHA Class II) and medical therapy is the first-line approach. Importantly, patients may become accustomed to their reduced functional capacity and minimize symptoms, making objective confirmation of functional capacity with cardiopulmonary exercise testing a useful adjunct to history-taking for assessment of exertional intolerance. Medical therapies include beta-blockade and verapamil alone or in combination, though verapamil may increase LVOTO-associated symptoms in some individuals due to its vasodilatory effect. Disopyramide may be added for patients with symptoms refractory to the use of beta-blocker or calcium channel blocker therapy.

• #10 Cardiomyopathy | Causes, Symptoms, Types & Treatment

  https://www.cincinnatichildrens.org/health/c/cardiomyopathy

  The more chronic treatment options for hypertrophic cardiomyopathy address both the heart rhythm problems and obstruction of flow problems. Treatment for outflow obstruction can include medicines such as beta blockers (atenolol, metoprolol) and calcium channel blockers (verapamil), designed to slow the heart rate and „relax” the heart, thereby decreasing the obstruction. […] Patients with restrictive cardiomyopathy are at high risk for blood clots within the heart, particularly the enlarged upper chambers. Blood thinners such as aspirin, coumadin (warfarin) or Lovenox may be needed. Gentle use of diuretics can also help some patients. Internal Cardioverter / Defibrillators (ICDs) are also used because these patients are at risk for sudden cardiac arrest related to fast or slow rhythms. […] Patients with ACM can benefit from treatment with medicines to limit abnormal rhythms. Treatment also consists of placement of an ICD to protect against sudden cardiac events such as a cardiac arrest. In certain cases, a catheter-based procedure to eliminate the abnormal rhythm can be performed.

• #11 Hypertrophic Cardiomyopathy – Cardiovascular Disorders – MSD Manual Professional Edition

  https://www.msdmanuals.com/professional/cardiovascular-disorders/cardiomyopathies/hypertrophic-cardiomyopathy

  Treatment is with beta-blockers, verapamil, disopyramide, mavacamten, and sometimes chemical reduction or surgical removal of outflow tract obstruction. […] Treatment of hypertrophic cardiomyopathy is based on the phenotype. Patients without obstruction generally have a stable clinical course without significant symptoms, although some experience heart failure symptoms due to diastolic dysfunction. Beta-blockers and heart rate-limiting calcium channel blockers with a lower arterial dilation capacity (usually verapamil), alone or combined, are the mainstays. By slowing the heart rate, they prolong the diastolic filling period, which may increase left ventricular filling in patients with diastolic dysfunction. Long-term efficacy of such therapy, however, has not been proven. […] In patients with the obstructive phenotype, in addition to attempts at improving diastolic function, treatment is directed at reducing the outflow tract gradient. Non-dihydropyridine calcium channel blockers (eg, verapamil, diltiazem), beta-blockers, and disopyramide reduce the outflow tract gradient through their negative inotropic effects.

• #12 Dilated Cardiomyopathy (DCM) Treatment & Management: Approach Considerations, Blood Pressure Control, Angiotensin-Converting Enzyme Inhibitors

  https://emedicine.medscape.com/article/152696-treatment

  Previously believed to be contraindicated in patients with left ventricular dysfunction, this class of medications has moved to the forefront of HF treatment. […] Spironolactone acts as an aldosterone receptor blocker and, with concomitant use of angiotensin-converting enzyme (ACE) inhibitors, helps break the cycle of sodium retention and fluid overload via the renin-aldosterone axis. […] Foxglove and its derivatives are the oldest treatment of HF, but they still have a place in medicine despite advances in other drug categories. […] Loop diuretics are necessary adjuncts in the medical therapy for HF when symptoms are due to sodium and water retention. […] Antiarrhythmics are useful in patients with supraventricular and nonsustained ventricular tachycardias. […] In 1986, the US Veterans Administration Cooperative study showed a 36% mortality risk reduction in patients treated with preload and afterload reducers (eg, isosorbide dinitrate, hydralazine) in addition to conventional HF medications.

• #13 Cardiomyopathy Guide: Causes, Symptoms and Treatment Options

  https://www.drugs.com/health-guide/cardiomyopathy.html

  The treatment of cardiomyopathy depends on its cause. Here are some of the more common treatments: […] medications that prolong life in people with dilated cardiomyopathy […] drugs that improve the symptoms of heart failure in dilated cardiomyopathy […] drugs that help to relax the heart muscle in hypertrophic cardiomyopathy […] SGLT2 inhibitors are the newest class of drugs that improve outcome in people with cardiomyopathy, especially those with dilated cardiomyopathy. […] A heart transplant may be necessary for patients whose poor heart function has become disabling or life threatening.

• #14 Reddit – The heart of the internet

  https://www.reddit.com/r/Cardiomyopathy/comments/18zh4gh/medication_therapy_for_patients_with_dcm/

  The purpose of your heart medications is (1) to help you live longer, (2) to improve your heart muscle function and reduce the stress on your heart, and (3) to help you feel better. […] In most cases, medications to improve heart muscle function are started at low doses and are increased over time. There are four major categories of medications that are recommended for persons with DCM and reduced ejection fraction. Medications from these four categories have been well studied and are proven to improve survival in this population. […] ACEI, ARBs, and ARNIs help improve heart muscle function and improve survival. […] Beta blockers may also tend to reduce your blood pressure, which if elevated, is another beneficial effect. […] Aldosterone antagonists or mineralocorticoids receptor antagonists (MRAs) show consistent improvements in survival, HF hospitalizations, and sudden cardiac death (SCD) in persons with DCM who have a reduced ejection fraction. […] Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the fourth category of medications that provide benefit to people with DCM and reduced ejection fraction of 40% or less. They reduce the risk of hospitalization for heart failure and cardiovascular death.

• #15 About Cardiomyopathy Caused by Chemotherapy | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/patient-education/about-cardiomyopathy-caused-chemotherapy

  Antiarrhythmic medications help control abnormal (not normal) heart rhythms. One example is amiodarone (Cordarone). […] Diuretics (water pills) help your body get rid of extra salt and fluid. They can help with swelling and can help you breathe better. One example is furosemide (Lasix). […] Left ventricular assist device (LVAD). This device helps your heart pump blood to the rest of your body. This can be a long-term treatment or a short-term treatment for people who are waiting for a heart transplant. […] Implantable cardioverter defibrillator (ICD). This device keeps track of your heart rate. If it senses a dangerous arrhythmia (abnormal heartbeat), the device will send an electric shock to your heart to help your heart return to a normal heartbeat. […] In a heart transplant surgery, a very diseased heart is replaced with a healthy heart from a donor. This surgery is only done if all other treatments options have failed.

• #16 Hypertrophic Cardiomyopathy (HCM) | American Heart Association

  https://www.heart.org/en/health-topics/cardiomyopathy/what-is-cardiomyopathy-in-adults/hypertrophic-cardiomyopathy

  Unlike other HCM medications, the cardiac myosin inhibitor mavacamten is used to improve symptoms and function in people with the obstructive type of HCM who have mild to moderate symptoms with activity. […] A range of surgical and nonsurgical procedures can be used to treat HCM: […] Septal myectomy, also called septal reduction therapy, is open-heart surgery. It’s considered for people with obstructive HCM who, despite taking HCM medications, continue to have severe symptoms. […] Alcohol septal ablation (nonsurgical procedure) – Also called nonsurgical septal reduction therapy, alcohol septal ablation is a procedure where ethanol (a type of alcohol) is injected through a tube into the small artery that supplies blood to the area of heart muscle thickened by HCM. […] Depending on specific patient risk factors, there are devices that can be implanted in the body to help the heart work better, including: […] In HCM patients with advanced, end-stage disease, a heart transplant may be considered.

• #17 Current Management and Treatment – Dilated Cardiomyopathy – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK553842/

  For patients with symptomatic HF, a new therapeutic algorithm has been proposed by the current European guidelines. Neurohormonal antagonists, ACEi or angiotensin II type I receptor blockers (ARB) in case of ACEi intolerance, are recommended from the beginning in association with beta-blocker. The addition of mineralocorticoid receptor antagonists (MRA) should be considered in patients still symptomatic with an optimized dosage of ACEi and beta-blocker. ACEi, ARB, beta-blocker, and MRA have demonstrated, in several clinical trials, to reduce risk of HF hospitalization and death in patient with HF and reduced EF. […] More recently, two new molecules have been included to the recommended pharmacological therapy: an angiotensin receptor-neprilysin inhibitor (ARNI) and the hyperpolarization channel blocker ivabradine. In particular, Sacubitril/Valsartan, tested in PARADIGM trial, is recommended for patients on optimal medical therapy, tolerating ACEi or ARB, but still in IIIII NYHA class. Ivabradine is indicated for patients in sinus rhythm that continue to have a resting heart rate over 70 bpm even on beta-blocker therapy based on SHIFT trial. Both these two drugs have shown to improve survival and reduce hospitalization in patients with HF. […] Finally, in case of intolerance or contraindication to ACEi or ARB, combination of hydralazine and isosorbide dinitrate in symptomatic patients with HF and reduced LVEF has demonstrated to reduce mortality.

• #18 What to Know About Medical Therapy for Cardiomyopathy | MedPage Today

  https://www.medpagetoday.com/medical-journeys/cardiomyopathy/101260

  What to Know About Medical Therapy for Cardiomyopathy […] The diverse range of cardiomyopathies demand a diverse set of treatments, but some overarching themes do apply across many clinical scenarios. […] For patients who develop heart failure with reduced ejection fraction of 40% or less (HFrEF), the „four cornerstones,” or „four pillars,” of treatment are: […] Renin-angiotensin system inhibition […] Beta-blocker […] Mineralocorticoid receptor antagonist (MRA) […] Sodium-glucose cotransporter 2 (SGLT2) inhibition […] For renin-angiotensin system inhibition, the 2022 American Heart Association/American College of Cardiology (AHA/ACC) guidelines recommend that HFrEF patients get angiotensin receptor-neprilysin inhibition with sacubitril/valsartan (Entresto) as the preferred agent, or an angiotensin-converting-enzyme (ACE) inhibitor when not feasible. The next in line for patients unable to tolerate an ACE inhibitor due to cough or angioedema is an angiotensin receptor blocker (ARB).

• #19 Hypertrophic Cardiomyopathy Treatment & Management: Approach Considerations, Left Ventricular Myomectomy and Mitral Valve Replacement, Pacemaker Implantation

  https://emedicine.medscape.com/article/152913-treatment

  Mavacamten, a first-in-class allosteric inhibitor of cardiac myosin, gained approval from the FDA for adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve exercise capacity and symptoms. […] Approval of mavacamten was based on results from the multicenter, phase 3 EXPLORER-HCM trial (n = 251). […] Avoid inotropic drugs if possible; also avoid nitrates and sympathomimetic amines, except in those patients with concomitant coronary artery disease. […] Pacemaker implantation has been a proposed treatment for patients with hypertrophic cardiomyopathy (HCM). […] Transvenous catheter ablation of the septal region has been performed using selective arterial ethanol infusion to destroy myocardial tissue. […] Alcohol septal ablation offers some advantages over surgical myectomy in that (1) it does not require surgical incision and/or general anesthesia, (2) the recovery time is shorter, and (3) its results lead to less discomfort and greater patient satisfaction than are reported with surgical myectomy.

• #20 Common types of medication | Cardiomyopathy UK

  https://www.cardiomyopathy.org/about-cardiomyopathy/medication

  Dapagliflozin in addition to standard care reduced the risk of worsening heart failure hospitalisation versus placebo by 26%. […] The EMPEROR-Reduced trial demonstrated in addition to standard care reduced the risk of hospitalisation for heart failure and cardiac death by 25%. […] Entresto is used in certain people with chronic heart failure. This medicine helps lower the risk of needing to be hospitalized when symptoms get worse, and helps lower the risk of death from heart failure. […] Mavacamten is a cardiac myosin inhibitor, which aims to normalise the contraction of the heart muscle, reduce the obstruction to blood leaving the heart and improve the ability of the heart to fill with blood. […] It is for adults diagnosed with hypertrophic cardiomyopathy with obstruction (where the thickening of the heart muscle affects blood leaving the heart) who have good pumping function of the heart who have symptoms due to the obstruction of blood leaving the heart.

• #21 Cardiomyopathy: Symptoms, Causes, and Treatment

  https://www.webmd.com/heart-disease/muscle-cardiomyopathy

  If your condition is serious and drugs dont improve your symptoms, your doctor may recommend a procedure such as: Alcohol septal ablation. This procedure, used for hypertrophic cardiomyopathy, shrinks part of the heart muscle that has grown too thick. To do it, your doctor uses a catheter to send alcohol into an artery that supplies blood to the area. […] Another option is surgery in which a doctor places a device in your heart to help it perform better. These include: Pacemaker, a device that stabilizes your heartbeat. Left ventricular assist device, a pump that sends blood out to the rest of your body. Implantable cardioverter defibrillator, which uses electrical shocks to correct heart rhythms. Cardiac resynchronization therapy device, which tracks irregular heart rhythms and delivers electrical shocks when needed.

• #22 Cardiomyopathy Treatment Options | Temple Health

  https://www.templehealth.org/services/conditions/cardiomyopathy/treatment-options

  The goal for treating cardiomyopathy is to reduce the frequency and severity of your symptoms. For some patients, this requires surgical intervention. Examples of surgical therapies include: Internal Cardioverter-defibrillator is used for patients with uncontrolled symptoms or at high risk, this device can help stop a life-threatening abnormal heartbeat. […] Pacemaker can help slow or regulate the heartbeat. […] Alcohol septal ablation is used in cases where the outflow of blood from the heart is blocked. By injecting alcohol in a coronary artery, your doctor can improve outflow. Alternatively, surgeons can perform a surgical septal myectomy that removes a strip of heart muscle to improve outflow. […] Angioplasty or bypass surgery can improve blood supply to the damaged heart. […] Mitral valve repair can also help the heart beat more effectively in some patients with cardiomyopathy; our surgeons offer robotic-assisted techniques of mitral valve repair to allow smaller incisions and faster recovery. […] Heart transplantation.

• #23 Hypertrophic cardiomyopathy – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/hypertrophic-cardiomyopathy/diagnosis-treatment/drc-20350204

  The goals of hypertrophic cardiomyopathy treatment are to ease symptoms and prevent sudden cardiac death in people at high risk. Treatment depends on how severe the symptoms are. […] Medicines can help reduce how strongly the heart muscle squeezes and slow the heart rate. That way, the heart can pump blood better. Medicines to treat hypertrophic cardiomyopathy and its symptoms might include: […] Several surgeries or procedures are available to treat cardiomyopathy or its symptoms. […] Septal myectomy helps improve blood flow out of the heart. It also reduces backward flow of blood through the mitral valve. […] The surgery can be done using different approaches, depending on the location of the thickened heart muscle. […] Surgical myectomy has been a very successful operation for many of our patients. However, it is not utilized as much as it maybe could be in part owing to prior perceptions about increased risk with the operation, lack of universal availability of surgeons who can do it.

• #24 Treatment of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to Know

  https://www.acc.org/Latest-in-Cardiology/Articles/2020/02/19/18/19/Treatment-of-Hypertrophic-Cardiomyopathy

  Septal reduction therapy (SRT) is indicated when medical therapy fails to control NYHA Class III symptoms or following LVOTO-associated syncope or near syncope refractory to medical therapy. There are two forms of SRT: surgical myomectomy and alcohol septal ablation. Surgical myectomy provides definitive therapy for symptomatic LVOTO and is associated with low post-operative mortality and morbidity when carried out by experienced operators in expert centers, although no significant long-term mortality benefit has been demonstrated. Given this, pre-operative counseling should emphasize that the benefit is currently limited to symptom improvement. […] With refinement of the techniques and greater experience, post-procedural outcomes following alcohol septal ablation are comparable to surgical myectomy in appropriately selected patients at expert centers. Selecting the right approach to SRT is challenging and should include not only the assessment of provider and center expertise, but also factors such as patient age, comorbid disease, and patient preference. Despite excellent intermediate and long-term results, some patients remain symptomatic or develop heart failure after SRT.

• #25 Cardiomyopathy

  https://www.nhs.uk/conditions/cardiomyopathy/

  Those with heart rhythm problems may need to have arrhythmia ablation. This treatment carefully alters the diseased heart tissue that causes the heart rhythm problems. […] Or they may have a device implanted, such as: a pacemaker to regulate the heart rate or an implantable cardioverter defibrillator (ICD) to prevent a life-threatening abnormal heart rhythm. […] As a last resort, a heart transplant may be necessary.

• #26 Cardiomyopathy Symptoms & Treatment | Baptist Health

  https://www.baptisthealth.com/care-services/conditions-treatments/cardiomyopathy

  In this procedure, a physician guides long, flexible tubes (catheters) through blood vessels to the heart. Electrodes at the catheter tips transmit radiofrequency energy to damage (ablate) a small spot of heart tissue that is causing an abnormal heart rhythm. […] During this procedure, a small portion of the thickened heart muscle is destroyed by injecting alcohol through a long, thin catheter into the artery supplying blood to that area. […] In this procedure, a surgeon removes part of the thickened heart muscle wall (septum) that separates the two ventricles. Removing this improves blood flow through the heart and reduces mitral valve regurgitation. […] A ventricular assist device (VAD) is an implantable mechanical pump designed to support heart function and blood flow in people who have weakened hearts. […] A heart transplant is the replacement of a persons diseased heart with a donors healthy heart.

• #27 Device Therapy for Cardiomyopathy & Heart Failure | NYU Langone Health

  https://nyulangone.org/conditions/cardiomyopathy-heart-failure/treatments/device-therapy-for-cardiomyopathy-heart-failure

  Your NYU Langone doctor may implant a wireless device called CardioMEMS. It measures the pressure in the pulmonary artery, which is the main blood vessel that carries blood from the heart to the lungs. This allows your doctor to track your heart function and your response to medication for heart failure. […] Implantable cardioverter defibrillators detect a life-threatening, rapid heartbeat called ventricular fibrillation and deliver a series of electrical pulses or an electrical shock, restoring the normal heart rhythm. This is known as defibrillation. […] People with dilated cardiomyopathy are often candidates for implantable defibrillators, as are some people with hypertrophic cardiomyopathy. […] A pacemaker a battery-operated device the size of two half-dollar pieces pressed together is implanted in the chest to keep the heart beating at a normal rate. The device sends electrical signals to your heart to help it maintain a regular rhythm.

• #28 Treatment of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to Know

  https://www.acc.org/Latest-in-Cardiology/Articles/2020/02/19/18/19/Treatment-of-Hypertrophic-Cardiomyopathy

  Patients with HCM are at increased risk for SCD, and risk stratification for implantable cardioverter defibrillator (ICD) implantation is critical in this population. Primary prevention with an ICD is reasonable for patients with severe hypertrophy (30mm), family history of sudden death in a first degree relative, recent unexplained syncope, or „burnt-out” HCM (LVEF 50%). The presence of non-sustained ventricular tachycardia on 24-hour Holter or abnormal blood pressure response to exercise, when added to other risk factors, also supports primary prevention ICD. Other risk factors that may influence the decision to place an ICD for primary prevention include marked late-gadolinium enhancement on magnetic resonance imaging (MRI), the presence of an apical aneurysm, and some genetic mutations present in families with high prevalence of sudden cardiac death. Secondary prevention with ICD placement in those surviving SCD or with sustained ventricular tachycardia (VT) is universally recommended. In the case of syncope, a thorough evaluation for provoked obstruction is first required to avoid ICD implantation for syncope related to LVOTO rather than ventricular arrhythmias. Periodic reassessment of risk factors is recommended as part of ongoing follow up, with more frequent testing reserved for younger patients and those with borderline risk factors.

• #29 Device Therapy for Cardiomyopathy & Heart Failure | NYU Langone Health

  https://nyulangone.org/conditions/cardiomyopathy-heart-failure/treatments/device-therapy-for-cardiomyopathy-heart-failure

  Biventricular pacemakers are typically used to manage arrhythmias, or irregular heartbeats, caused by heart failure. This condition causes the organs lower left chamber, or ventricle, to pump erratically. […] NYU Langone heart surgeons typically implant the pacemaker under the skin, below the right or left collarbone. Pacemaker implantation is performed using a sedative as well as a local anesthetic at the implantation site. It takes 30 to 60 minutes to complete and requires an overnight hospital stay.

• #30 Breaking Down Options for Cardiomyopathy Treatment | CVRTI

  https://cvrti.utah.edu/breaking-down-the-treatment-options-for-cardiomyopathy/

  Medication is often an essential component in the management of cardiomyopathy. Commonly prescribed medications include Angiotensin-Converting Enzyme (ACE) Inhibitors, beta-blockers, and the use of diuretics. […] Finally, anticoagulants may be administered in certain circumstances, particularly in cases where cardiomyopathy is linked with atrial fibrillation, to avoid blood clots and lower the risk of stroke. […] Beyond the treatment options listed above, there are a few others that might be considered. These include ICDs, implantable cardioverter-defibrillators, or Cardiac Resynchronization Therapy for heart failure(CRT). CRT involves the implantation of a device that is responsible for coordinating the contractions of the ventricles of the heart. When it comes to some instances of heart failure that are related to cardiomyopathy, this can be useful.

• #31 Cardiomyopathy Treatment

  https://www.dukehealth.org/treatments/heart/cardiomyopathy

  A battery-powered ICD offers protection against unpredictable arrhythmias. The device is surgically implanted under your skin. Thin wires placed within or near your heart muscle continuously monitor your heart rhythm and can pace or shock the heart back into rhythm if a life-threatening arrhythmia develops. This device is recommended for people with certain types of cardiomyopathy and who have certain risk factors, such as extremely thick heart muscle or severely reduced heart strength. […] If cardiomyopathy has severely weakened your heart, leading to heart failure, you may be a candidate for a VAD. This mechanical heart pump can support your heart and optimize your blood flow while you’re waiting for a heart transplant. It can also be a long-term solution if you have heart failure and are not a candidate for a heart transplant.

• #32 Dilated Cardiomyopathy (DCM) Treatment & Management: Approach Considerations, Blood Pressure Control, Angiotensin-Converting Enzyme Inhibitors

  https://emedicine.medscape.com/article/152696-treatment

  Human B-type natriuretic peptide (BNP) (nesiritide [Natrecor]) is a relatively new class of drug in the treatment of HF. […] Long-term use of the phosphodiesterase inhibitor milrinone has deleterious effects on survival in patients with HF. […] Restrict the use of anticoagulants to those patients in atrial fibrillation, with artificial valves, or with known mural thrombus. […] Implantable left ventricular assist devices (LVADs) have been proven as a standard of care for suitable candidates with advanced HF when a bridge to transplantation (BTT) is needed. […] For biventricular pacing, a pulse generator is implanted under the skin, with leads positioned in the right atrium, right ventricle, and coronary sinus to pace the left ventricle. […] Automatic implantable cardioverter-defibrillators (AICDs) are designed to detect and correct ventricular tachycardia/ventricular fibrillation.

• #33

  https://www.nhs.uk/conditions/heart-failure/treatment/

  Some people with heart failure will need to have a procedure to implant a small device in their chest that can help control or monitor their heart’s rhythm. […] Medicines are the main treatment for heart failure, but for some people surgery may help. […] Operations that can help with heart failure include: heart valve surgery, a coronary angioplasty or bypass, left ventricular assist devices, heart transplant. […] A heart transplant may be necessary if you develop severe heart failure that can’t be treated effectively with medication or other types of surgery.

• #34 Dilated Cardiomyopathy – Cardiovascular Disorders – Merck Manual Professional Edition

  https://www.merckmanuals.com/professional/cardiovascular-disorders/cardiomyopathies/dilated-cardiomyopathy

  Patients with refractory heart failure despite treatment may become candidates for heart transplantation. Selection criteria include absence of associated systemic disorders and psychologic disorders and high, irreversible pulmonary vascular resistance; because donor hearts are scarce, younger patients (usually 70 years) are given higher priority. Left ventricular assist devices (LVAD) may also be considered as a bridge to heart transplantation or as destination therapy in some patients (eg, patients who are not eligible for heart transplantation).

• #35 Treatment of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to Know

  https://www.acc.org/Latest-in-Cardiology/Articles/2020/02/19/18/19/Treatment-of-Hypertrophic-Cardiomyopathy

  Some patients with HCM develop clinical heart failure, ranging from heart failure with preserved ejection fraction, to severe restrictive cardiomyopathy, to 'burnt-out’ dilated hypertrophic cardiomyopathy. Patients diagnosed with HCM prior to age 40 have more than a 60% chance of experiencing clinical heart failure by age 70, and those diagnosed between ages 40 and 60 have greater than a 40% chance to experience heart failure by that age. However, only 5% of HCM patients will progress to require advanced heart failure therapies during their lifetime. […] Given the predominant restrictive physiology with fixed stroke volume and small left ventricular cavity, patients often do not respond to inotropic support or benefit from implantation of a durable left ventricular assist device (LVAD). This is reflected in the 2018 United Network for Organ Sharing (UNOS) allocation guidelines for heart transplantation, which affords HCM patients higher outpatient priority listing at Status 4 than other outpatient transplant candidates with ischemic or dilated cardiomyopathy, who are Status 6.

• #36 Diagnosing and Treating HCM | OHSU

  https://www.ohsu.edu/knight-cardiovascular-institute/hypertrophic-cardiomyopathy-treatment-options

  Hypertrophic cardiomyopathy can be difficult to diagnose. But thanks to advancements in treatment, many people can manage their HCM with minimal symptoms. Researchers at OHSUs HCM Center of Excellence and beyond are developing new medicines like cardiac myosin inhibitors to treat the root cause of HCM. […] Your treatment may include: […] Cardiac myosin inhibitors are very effective because they target the root cause of HCM. They help your heart beat less forcefully, which can reduce your symptoms and make it easier for you to exercise. For now, these medications are approved for people with obstructive HCM. […] If medications haven’t worked to manage your HCM, your doctor may recommend surgery called septal myectomy. […] We will carefully evaluate whether you are at risk of dying suddenly from a dangerous heart rhythm. If your risk is high, your doctor will talk to you about an implantable defibrillator.

• #37 Treatment of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to Know

  https://www.acc.org/Latest-in-Cardiology/Articles/2020/02/19/18/19/Treatment-of-Hypertrophic-Cardiomyopathy

  Atrial fibrillation can worsen exertional symptoms and increase stroke risk in patients with HCM. The role for catheter ablation has not been specifically studied in HCM cohorts but remains an option for patients with symptoms refractory to medical therapy. As refractory symptomatic atrial fibrillation often marks progressive disease with restrictive physiology, these patients also warrant evaluation for advanced heart failure therapies such as heart transplantation. Due to the increased risk for thromboembolism in HCM patients who develop atrial fibrillation or flutter, oral anticoagulation is recommended as primary stroke prophylaxis regardless of CHA2DS2-VASc score. […] Balancing the overall benefits of exercise in the general population with the potential risk of SCD in the HCM population is a challenge. Strenuous exercise has been routinely discouraged, though there is an increasing appreciation for how the health benefits of exercise should be balanced with the potential risks. Studies to better define the risk of high-intensity exercise in HCM are ongoing, and thoughtful discussion with shared decision making is a widely accepted strategy for application of exercise restrictions in this population.

• #38 What to Know About Medical Therapy for Cardiomyopathy | MedPage Today

  https://www.medpagetoday.com/medical-journeys/cardiomyopathy/101260

  For heart failure with preserved ejection fraction, the strongest recommendation was to control blood pressure, followed by a 2a recommendation for management of atrial fibrillation to ease symptoms and for use of SGLT2 inhibitors. Selected patients could also be considered for MRAs, ARBs, and sacubitril/valsartan, especially on the lower end of the ejection fraction range. […] For medical management in hypertrophic cardiomyopathy (HCM), the 2020 AHA/ACC guidelines recommended direct oral anticoagulants for persistent or paroxysmal atrial fibrillation as the default, regardless of CHA2DS2VASc score. […] For patients with symptomatic left ventricular outflow tract obstruction (LVOTO), the guidelines gave a class 1 recommendation to nonvasodilating beta-blockers (or nondihydropyridine calcium channel blockers if not tolerated or ineffective) and to the addition of disopyramide in cases of persistent severe symptoms from LVOTO despite those agents.

• #39 What to Know About Medical Therapy for Cardiomyopathy | MedPage Today

  https://www.medpagetoday.com/medical-journeys/cardiomyopathy/101260

  For patients with obstructive HCM, the guidelines gave a class 1 endorsement of vasoconstrictors without inotropic activity (alone or with beta-blockers) for acute hypotension unresponsive to fluid administration and a class 2b recommendation for cautious use of low-dose oral diuretics for persistent dyspnea with volume overload and high left-sided filling pressures. […] For patients with restrictive cardiomyopathy (RCM), aside from treating any identified underlying cause, heart failure management with the usual agents is complicated, noted a review in Circulation Research by Morie Gertz, MD, and colleagues. […] Volume status can be challenging to manage with diuretics, „as patients with RCM rely on high filling pressures to maintain cardiac output and excessive diuresis may result in tissue hypoperfusion,” the authors explained. „The use of beta-blockers or calcium channel blockers to increase filling time or to manage arrhythmias should be carefully introduced, as some patients may be intolerant.”

• #40 Restrictive Cardiomyopathy | Cedars-Sinai

  https://www.cedars-sinai.org/health-library/diseases-and-conditions/r/restrictive-cardiomyopathy.html

  The causes of RCM can be hard to treat. The treatment is often centered around the underlying cause. For example, chelation therapy or phlebotomy may help RCM caused by too much iron in the body. Chelation therapy uses drugs that bind to iron and removes it from the body. Phlebotomy removes some of the iron-loaded blood from the body through an IV line. A bone marrow transplant may be used to treat RCM caused by amyloidosis. It replaces cells that make the amyloid proteins. […] Your healthcare provider may prescribe treatments to help reduce your symptoms, such as: […] Water pills (diuretics) to reduce swelling […] Medicine, such as heart-rate-lowering calcium channel blockers or beta-blockers, to reduce the hearts workload and increase its efficiency […] Medicine, such as ACE inhibitors, to help the heart pump better

• #41 What to Know About Medical Therapy for Cardiomyopathy | MedPage Today

  https://www.medpagetoday.com/medical-journeys/cardiomyopathy/101260

  ACE inhibitors and angiotensin II receptor blockers aren’t well proven for these patients and may not be well tolerated. […] On the other hand, most patients stand to benefit from anticoagulation, due to elevated risk of left atrial thrombus. That’s especially the case for cardiac amyloidosis patients, for whom anticoagulation has a class 2a recommendation with atrial fibrillation regardless of CHA2DS2-VASC risk score and for those with an enlarged atrium even when in sinus rhythm, according to a review in Current Treatment Options in Oncology. […] For cardiac amyloidosis, most supportive medications for heart failure management are not well tolerated, the review by Gertz and co-authors noted. „Angiotensin-converting enzyme inhibitors and angiotensin receptor II blockers often lead to profound hypotension, even in modest doses. Beta-blockers and calcium channel blockers may aggravate hypotension because of the fixed stroke volume and need for a higher heart rate to maintain cardiac output.”

• #42 Cardiomyopathy Treatment | UVA Health

  https://uvahealth.com/services/heart/cardiomyopathy-treatment

  Cardiomyopathy Treatment at UVA Health […] There isn’t a cure for cardiomyopathy. But we can help you manage the symptoms and keep it from progressing quickly. We can help you understand what your heart is doing so you can help improve your symptoms. And well work with you to create a long-term care plan thats right for you. […] Treatment options depend on: […] Cardiomyopathy type […] How bad the symptoms are […] Your age and overall health […] Lifestyle changes can help slow down the progress of cardiomyopathy. That means: […] Eating a heart-healthy diet […] Getting regular exercise […] Avoiding alcohol and smoking […] Watching your stress levels […] Watching your weight […] If you need cardiomyopathy treatment, we can use: […] Medication […] We can improve blood flow or treat symptoms with:

• #43 About Cardiomyopathy | Heart Disease | CDC

  https://www.cdc.gov/heart-disease/about/cardiomyopathy.html

  Cardiomyopathy can be acquireddeveloped because of another disease, condition, or factoror inherited. […] Treatment may include medications, changes to physical activity, or surgery. […] The goal of treatment is to slow down the disease, control symptoms, and prevent sudden death. If you are diagnosed with cardiomyopathy, your doctor may tell you to change your diet and physical activity, reduce stress, avoid alcohol and other drugs, and take medicines. Your doctor may also treat you for the conditions that led to cardiomyopathy, if they exist, or recommend surgery. Treatment also depends on which type of cardiomyopathy you have. […] Adopting or following a healthier lifestyle can help control symptoms and complications. If you have an underlying disease or condition that can cause cardiomyopathy, early treatment of that condition can help prevent the disease from developing.

• #44 Cardiomyopathy | Heart and Stroke Foundation

  https://www.heartandstroke.ca/heart-disease/conditions/cardiomyopathy

  If cardiomyopathy is properly treated and controlled, many people with the condition can manage with just a few changes to their normal lifestyle. Some people might need to make major adjustments to their lifestyle. If you are told to limit or avoid some sports or activities, there are other light-to-moderate physical activities that can help you to remain healthy and avoid other heart problems. It is important to talk to your cardiologist about how you can live a healthy, active lifestyle without risking further complications. […] A dietitian can advise you about healthy eating. They can provide tips to manage your fluid and salt intake to help your heart. […] Giving up alcohol completely is a good idea. Losing weight can also help relieve symptoms by reducing the burden on your heart. […] Talk to your doctor about the lifestyle changes that will benefit you the most.

• #45 Treatment of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to Know

  https://www.acc.org/Latest-in-Cardiology/Articles/2020/02/19/18/19/Treatment-of-Hypertrophic-Cardiomyopathy

  There are currently no medical interventions that alter the natural course of HCM, but cardiac myosin inhibitors have shown potential promise. Trials investigating the effect of cardiac myosin inhibitors such as mavacamten and CK-274 on LVOTO and HCM associated diastolic heart failure are underway. Finally, gene-silencing with CRISPR/Cas9 gene-editing technology may someday play a role in the prevention of disease development before the appearance of clinical manifestations. […] In summary, patients with HCM may suffer from LVOTO obstruction, atrial arrhythmias, SCD, and advanced heart failure. Current therapies focus on the disease manifestations, but future therapies may offer hope to effectively address the pathophysiology of HCM. Until then, recognition of the role of medical, interventional, device, and surgical therapies, and the use of shared decision making in areas of exercise prescription, are essential to improve the quality of life and survival of patients with HCM.

• #46 CureHeart | Cardiomyopathy Gene Therapy | Cardiomyopathy UK

  https://www.cardiomyopathy.org/cureheart

  The BHF funded CureHeart research project aims to find the world’s first cures for inherited cardiomyopathies. […] Researchers at the University of Oxford, led by Professor Hugh Watkins, will develop gene therapies for cardiomyopathy in people with an inherited heart condition. […] CureHeart will use gene therapy which enables the faulty gene to be repaired or replaced to treat cardiomyopathy by targeting the specific fault, to correct the action of the gene in a person’s heart cells. […] Yes. The treatment will target the specific genetic cause of cardiomyopathy in a person or family, and will be tailored to the genetic fault. […] Existing medical treatments for cardiomyopathy are not always effective, and some (such as surgical procedures or devices) can be risky. […] Gene therapy will depend on the type of genetic fault a person has, and the way it acts to change the protein function.

• #47 Shifting Paradigms in Dilated Cardiomyopathy Treatment

  https://www.delveinsight.com/blog/evolving-dilated-cardiomyopathy-treatment

  The emerging treatment strategies for DCM are based on regenerative medicine approaches, such as stem cell therapy and gene therapy that have the potential to repair and restore myocardia functioning in patients. […] Stem cell therapy involves transplanting stem cells into the heart to improve cardiac function. Research indicates that stem cell transplantation can improve left ventricular ejection fraction (LVEF), increase exercise capacity, and alleviate symptoms of heart failure in patients with DCM. Various stem cell types have been employed in DCM treatment, such as skeletal myoblasts, hematopoietic stem cells, mesenchymal stem cells, and CD34+ stem cells. Human pluripotent stem cell-derived cardiac cells are being explored for their potential in disease modeling, cell therapy, and drug discovery. However, stem cell therapy effectiveness remains uncertain due to limited high-quality studies and the need for further exploration.

• #48 Stem Cell Treatment for Dilated Cardiomyopathy: A Review of Recent Scientific Advances | Published in Georgetown Medical Review

  https://gmr.scholasticahq.com/article/123163-stem-cell-treatment-for-dilated-cardiomyopathy-a-review-of-recent-scientific-advances

  Cardiomyopathy, a disorder of mechanical and electrical cardiac action, is a significant cause of morbidity and mortality in the United States and is seen in both adult and pediatric populations. Traditional treatment for dilated cardiomyopathy largely focuses on symptomatic relief and delayed progression of disease but does not offer a cure or reversal of disease process. […] Because existing management strategies for DCM are not able to fully prevent patients from progressing to heart failure, the use of stem cells offers a promising alternative. […] While stem cell therapy is a rapidly evolving area of research, several methods of stem cell derivation have proven particularly effective in the treatment of DCM. […] Because DCM often causes diffuse dilation, aspects of HSC therapy on other regions of the heart have shown similar promise.

• #49 Shifting Paradigms in Dilated Cardiomyopathy Treatment

  https://www.delveinsight.com/blog/evolving-dilated-cardiomyopathy-treatment

  Current therapeutic strategies for DCM are often limited in both effectiveness and accessibility, making heart transplantation the only viable option for patients with advanced stages of the disease. Many of these approaches rely on processes active in dividing cells, which limits their applicability for mature cells like cardiomyocytes and nerve cells that do not divide. However, recent advances in gene editing technologies like CRISPR-Cas9, stem cell therapy, gene modification, and others offer new, more effective, and targeted treatments that hold promise for improving treatment outcomes in DCM patients.

• #50 Shifting Paradigms in Dilated Cardiomyopathy Treatment

  https://www.delveinsight.com/blog/evolving-dilated-cardiomyopathy-treatment

  While current dilated cardiomyopathy treatments focus on controlling symptoms and improving heart function, there is a need for more innovative approaches to address the underlying causes of DCM and improve patient outcomes. […] Personalized medicine approaches focus on customizing dilated cardiomyopathy treatments for individual patients based on their unique genetic profiles, disease mechanisms, and therapy responses. These may include gene therapy, gene editing, and targeted treatments. This approach offers several advantages, including improved efficacy and reduced side effects. Personalized dilated cardiomyopathy treatment can be designed to target specific genetic mutations or disease mechanisms, increasing the likelihood of effective therapy. Additionally, personalized dilated cardiomyopathy treatment can help identify patients who are most likely to benefit from a particular therapy, reducing the risk of ineffective or harmful treatments as well as more precise monitoring and adjustment of treatment, enabling clinicians to optimize therapy over time.

• #51 Breaking Down Options for Cardiomyopathy Treatment | CVRTI

  https://cvrti.utah.edu/breaking-down-the-treatment-options-for-cardiomyopathy/

  A third option, Ventricular aid Devices (VADs), involves the use of mechanical pumps that insert themselves into the chest to aid the heart in pumping blood. In extreme situations of heart failure, they are frequently utilized as a transitional step on the path to heart transplantation. […] The therapeutic landscape for cardiomyopathy is diverse and multimodal, which is reflective of the complexity of this disorder. It is often the case that the key to properly controlling cardiomyopathy and enhancing the quality of life for those who are affected by it is to adopt a comprehensive strategy that incorporates lifestyle modifications and modern treatment methods. […] There is hope that, as research and medical developments continue, more targeted and individualized medications will emerge, which will further improve the prognosis for those who are struggling with this tough cardiac issue.

• #52 Cardiomyopathy: Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/16841-cardiomyopathy

  Cardiomyopathy treatment can improve your outlook. If you have cardiomyopathy, seek treatment from a cardiologist (heart specialist). Medication, procedures or other treatments can increase your quality of life and help you live longer. […] Theres no cure for cardiomyopathy. However, you can manage the condition or slow its progression. Many people who make healthy lifestyle choices and seek medical treatment can live a high quality of life with cardiomyopathy. Taking the proper medications can drastically alter and improve the prognosis of cardiomyopathy. Many people can live normal and healthy lives with the right treatment. […] Cleveland Clinic offers personalized diagnosis and the latest treatments for hypertrophic cardiomyopathy.

Zobacz więcej